Drug Discovery

How to Build a Mechanism-of-Action Hypothesis

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

For How to Build a Mechanism-of-Action Hypothesis, the bounded choice is which causal chain connects an intervention to a disease-relevant outcome. Compare at least three live alternatives using binding or perturbation, pathway response, temporal order, dose response, rescue, alternatives, and off-target effects, then run the cheapest ranking-reversal test: predict an orthogonal perturbation or rescue result before running it. The defensible output is pursue, reframe, or stop—not final validation.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which causal chain connects an intervention to a disease-relevant outcome

Why the problem is difficult

The article-specific identification challenge is whether the question “which causal chain connects an intervention to a disease-relevant outcome” can be resolved using binding or perturbation, pathway response, temporal order, dose response, rescue, alternatives, and off-target effects, rather than merely restated in new language.

A falsifier-first workflow

  • Define the decision precisely: which causal chain connects an intervention to a disease-relevant outcome.
  • Build a source and data ledger around binding or perturbation, pathway response, temporal order, dose response, rescue, alternatives, and off-target effects.
  • Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
  • Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
  • Run the lowest-cost discriminating challenge: predict an orthogonal perturbation or rescue result before running it.
  • Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

  • Decision impact: would the result materially change the choice about which causal chain connects an intervention to a disease-relevant outcome?
  • Evidence fit: does the available evidence—binding or perturbation, pathway response, temporal order, dose response, rescue, alternatives, and off-target effects—directly address the decision rather than merely correlate with it?
  • Discrimination: does the preferred route predict an outcome a credible alternative does not?
  • Robustness: does the ranking survive the challenge “predict an orthogonal perturbation or rescue result before running it”?
  • Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

binding or perturbation, pathway response, temporal order, dose response, rescue, alternatives, and off-target effects

Counterevidence

For this decision, a result from “predict an orthogonal perturbation or rescue result before running it” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which causal chain connects an intervention to a disease-relevant outcome or exposes why the available evidence cannot resolve it.

Fastest falsifier

predict an orthogonal perturbation or rescue result before running it

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “predict an orthogonal perturbation or rescue result before running it” without an independently supported alternative mechanism.

Evidence ceiling

A plausible MoA story is not demonstrated without discriminating evidence.

Sources and starting points

  • Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
  • ChEMBL — Curated bioactivity information for compounds, assays, and targets.
  • ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
  • PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
  • PubChem — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
  • FDA Drug Development and Approval Process — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

  1. Drug Target Prioritization: A Falsifier-First Framework
  2. Target Identification vs Target Validation in Drug Discovery
  3. What Counts as Evidence for Drug Target Validation?
  4. Map the Translational Gap Before Advancing a Drug Program

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “How to Build a Mechanism-of-Action Hypothesis” help make?
It supports a bounded decision about which causal chain connects an intervention to a disease-relevant outcome. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?
predict an orthogonal perturbation or rescue result before running it
Can computation validate the final scientific claim?
No. A plausible MoA story is not demonstrated without discriminating evidence. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?
Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.